{"id":"fuzeon-enfuvirtide","safety":{"commonSideEffects":[{"rate":"~98","effect":"Injection site reactions (pain, erythema, induration, nodules)"},{"rate":"~1","effect":"Hypersensitivity reactions"},{"rate":"~5","effect":"Pneumonia"},{"rate":"~20","effect":"Diarrhea"},{"rate":"~15","effect":"Nausea"},{"rate":"~15","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Enfuvirtide is a fusion inhibitor that binds to the HR1 region of gp41, an envelope glycoprotein essential for HIV entry. By blocking the conformational changes required for viral-cell membrane fusion, it prevents the virus from entering and infecting CD4+ T lymphocytes. This is the first FDA-approved HIV entry inhibitor and represents a distinct mechanism from reverse transcriptase and protease inhibitors.","oneSentence":"Enfuvirtide blocks HIV from entering CD4+ T cells by binding to the gp41 fusion protein on the viral envelope and preventing membrane fusion.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:30:18.655Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-experienced patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy"}]},"trialDetails":[],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"ACCIDENTAL NEEDLE STICK"},{"count":1,"reaction":"DEVICE FAILURE"},{"count":1,"reaction":"IMPAIRED WORK ABILITY"},{"count":1,"reaction":"INJECTION SITE DISCOLOURATION"},{"count":1,"reaction":"INJECTION SITE REACTION"}],"_approvalHistory":[],"publicationCount":110,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"FUZEON [enfuvirtide]","genericName":"FUZEON [enfuvirtide]","companyName":"Hoffmann-La Roche","companyId":"roche","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Enfuvirtide blocks HIV from entering CD4+ T cells by binding to the gp41 fusion protein on the viral envelope and preventing membrane fusion. Used for HIV-1 infection in treatment-experienced patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}